PMID- 22481636 OWN - NLM STAT- MEDLINE DCOM- 20120820 LR - 20220409 IS - 1424-3997 (Electronic) IS - 0036-7672 (Linking) VI - 142 DP - 2012 TI - Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. PG - w13567 LID - 10.4414/smw.2012.13567 [doi] AB - PRINCIPLES: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines aim to optimise chronic obstructive pulmonary disease (COPD) diagnosis and treatment. However, little is known about the extent to which general practitioners' (GP) adherence to GOLD guidelines improves patient outcomes. METHODS: In this questionnaire-based study, COPD patients were screened and enrolled; exacerbation history was recorded, and demographic, spirometric and management data were collected for 12 months. Spirometry was performed at least every 6 months according to American Thoracic Society guidelines. Based on these data, patients were grouped into GOLD COPD severity classifications. Data were expressed as the difference between baseline and month 12. RESULTS: Among 139 GPs, 454 patients were analysed regarding baseline and 12 month data. There was no significant change in distribution of GOLD COPD severity grades, lung function or guideline adherence. Chronic cough and sputum production were significantly reduced (p <0.001; p <0.020), as was exacerbation rate (p = 0.041). Factors associated with exacerbations were male sex, asthma and cerebrovascular insult as a co-morbidity. Exacerbation rate was significantly reduced in patients treated with combination therapy (long-acting beta2-agonist (LABA)+ inhaled corticosteroids (ICS); p = 0.0178) and long-acting anticholinergics (LAAC; p = 0.0011). Patients treated per guidelines had no advantage in lung function, estimation of symptom prevalence or, most importantly, exacerbation rate. CONCLUSIONS: While there was no improvement in adherence to GOLD guidelines, disease severity was not affected detrimentally, suggesting that guideline adherence does not seem to impact symptom prevalence, exacerbation rate or lung function decline after one year of follow up. FAU - Jochmann, Anja AU - Jochmann A AD - Clinic of Internal Medicine, University Hospital of Basel, Switzerland. FAU - Scherr, Andreas AU - Scherr A FAU - Jochmann, Dirk Christian AU - Jochmann DC FAU - Miedinger, David AU - Miedinger D FAU - Torok, Salome Schafroth AU - Torok SS FAU - Chhajed, Prashant N AU - Chhajed PN FAU - Tamm, Michael AU - Tamm M FAU - Leuppi, Jorg Daniel AU - Leuppi JD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120405 PL - Switzerland TA - Swiss Med Wkly JT - Swiss medical weekly JID - 100970884 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Adrenergic beta-2 Receptor Agonists) RN - 0 (Bronchodilator Agents) RN - 0 (Cholinergic Antagonists) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Adrenergic beta-2 Receptor Agonists/therapeutic use MH - Aged MH - Aged, 80 and over MH - Bronchodilator Agents/therapeutic use MH - Cholinergic Antagonists/therapeutic use MH - Cough/etiology MH - *Disease Progression MH - Drug Therapy, Combination MH - Exercise MH - Female MH - General Practice MH - *Guideline Adherence MH - Humans MH - Male MH - Middle Aged MH - Practice Guidelines as Topic MH - Pulmonary Disease, Chronic Obstructive/*diagnosis/physiopathology/*therapy MH - Severity of Illness Index MH - Smoking MH - Spirometry MH - Sputum/metabolism MH - Surveys and Questionnaires MH - Switzerland MH - Treatment Outcome EDAT- 2012/04/07 06:00 MHDA- 2012/08/21 06:00 CRDT- 2012/04/07 06:00 PHST- 2012/04/07 06:00 [entrez] PHST- 2012/04/07 06:00 [pubmed] PHST- 2012/08/21 06:00 [medline] AID - smw-13567 [pii] AID - 10.4414/smw.2012.13567 [doi] PST - epublish SO - Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567. eCollection 2012.